|
|
|
| Influencing factors and interventions of defecation disorders after orthopedic surgery: a review |
| NI Jing1, MA Chaomeng1, XIANG Sicheng1, JIA Wengping1, ZHANG Yan1, XU Li2
|
1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China;
2. The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China |
|
|
|
|
Abstract Defecation disorder is one of the most common complications after orthopedic surgery, which seriously affects patients' quality of life. Based on review of national and international publications pertaining to influencing factors and interventions of postoperative defecation disorders, this review analyzes the associations of orthopedic surgery-related factors with postoperative defecation disorders, and summarizes the common interventions for postoperative defecation disorders, including medication, physical therapy and daily life management, so as to provide insights into prevention and treatment of defecation disorders after orthopedic surgery.
|
|
Received: 26 September 2022
Revised: 02 December 2022
Published: 21 February 2023
|
|
|
|
|
|
[1] ROSS-ADJIE G M,MONTEROSSO L,BULSARA M.Bowel management post major joint arthroplasty:results from a randomised controlled trial[J].Int J Orthop Trauma Nurs,2015,19(2):92-101.
[2] 颜廷法,李倩倩,孙飞,等.关节置换患者术后便秘的相关因素分析[J].泰山医学院学报,2019,40(7):505-508.
[3] 陈巧林. 关节置换患者术后便秘的相关因素与护理对策[J].中国社区医师,2017,33(21):145-146.
[4] PODZEMNY V,PESCATORI L C,PESCATORI M.Management of obstructed defecation[J].World J Gastroenterol,2015,21(4):1053-1060.
[5] HOLTE K,KEHLET H.Postoperative ileus:a preventable event[J].Br J Surg,2000,87(11):1480-1493.
[6] MCCORMICK D.Managing costs and care for chronic idiopathic constipation[J].Am J Manag Care,2019,25(Suppl.4):S63-S69.
[7] ARTINYAN A,NUNOO-MENSAH J W,BALASUBRAMANIAM S,et al.Prolonged postoperative ileus-definition,risk factors,and predictors after surgery[J].World J Surg,2008,32(7):1495-1500.
[8] 刘菊新. 骨科长期卧床病人便秘原因的分析与对策[J].长治医学院学报,2004(1):64-65.
[9] FARMER A D,HOLT C B,DOWNES T J,et al.Pathophysiology,diagnosis,and management of opioid-induced constipation[J].Lancet Gastroenterol Hepatol,2018,3(3):203-212.
[10] 刘立波,陈朝军,凌洁.骨科卧床病人便秘原因分析及护理对策[J].湖南师范大学学报(医学版),2010,7(3):72-74.
[11] KIELY P D,MOUNT L E,DU J Y,et al.The incidence and risk factors for post-operative ileus after spinal fusion surgery:a multivariate analysis[J].Int Orthop,2016,40(6):1067-1074.
[12] AL MAAIEH M A,DU J Y,AICHMAIR A,et al.Multivariate analysis on risk factors for postoperative ileus after lateral lumbar interbody fusion[J].Spine,2014,39(8):688-694.
[13] 唐雨亭,方立俭.骶神经刺激疗法治疗便秘的现状及机制探讨[J].吉林医学,2018,39(4):745-748.
[14] HOLZER P.Opioid receptors in the gastrointestinal tract[J].Regul Pept,2009,155(1/2/3):11-17.
[15] CHEN C,ZHANG L,ALMANSA C,et al.Evaluation of the pharmacokinetics of felcisetrag(TAK-954),a 5-HT4 receptor agonist,in the presence and absence of itraconazole,a potent CYP3A4 inhibitor[J].Clin Pharmacol Drug Dev,2022,11(2):142-149.
[16] BENYAMIN R,TRESCOT A,DATTA S,et al.Opioid complications and side effects[J].Pain Physician,2008,11:S105-S120.
[17] COLVIN L A,BULL F,HALES T G.Perioperative opioid analgesia-when is enough too much?A review of opioid-induced tolerance and hyperalgesia[J].Lancet,2019,393(10180):1558-1568.
[18] SINGLA N K,SKOBIERANDA F,SOERGEL D G,et al.APOLLO-2:a Randomized,Placebo and Active-Controlled Phase Ⅲ study investigating oliceridine(TRV130),a G protein-biased ligand at the μ-opioid receptor,for management of moderate to severe acute pain following abdominoplasty[J].Pain Practice,2019,19(7):715-731.
[19] LEPPERT W,ZAJACZKOWSKA R,WORDLICZEK J.The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation[J].Expert Opin Pharmacother,2019,20(5):511-522.
[20] YUAN C S,FOSS J F.Methylnaltrexone:investigation of clinical applications[J].Drug Dev Res,2000,50(2):133-141.
[21] FLOETTMANN E,BUI K,SOSTEK M,et al.Pharmacologic profile of naloxegol,a peripherally acting µ-opioid receptor antagonist,for the treatment of opioid-induced constipation[J].J Pharmacol Exp Ther,2017,361(2):280-291.
[22] 韦良臣,谭振,周报春,等.莫沙必利联合地塞米松对全膝关节置换术术后早期康复的影响[J].中华实用诊断与治疗杂志,2021,35(12):1285-1289.
[23] SWARM R A,PAICE J A,ANGHELESCU D L,et al.Adult cancer pain,version 3.2019,NCCN clinical practice guidelines in oncology[J/OL].J Natl Compr Canc Netw,2019,17(8)[2022-12-17].https://doi.org/10.6004/jnccn.2019.0038.
[24] LACY B E,LEVY L C.Lubiprostone:a novel treatment for chronic constipation[J].Clin Interv Aging,2008,3(2):357-364.
[25] LEMBO A J,JOHANSON J F,PARKMAN H P,et al.Long-term safety and effectiveness of lubiprostone,a chloride channel(ClC-2)activator,in patients with chronic idiopathic constipation[J].Dig Dis Sci,2011,56(9):2639-2645.
[26] SHAH E D,KIM H M,SCHOENFELD P.Efficacy and tolerability of guanylate cyclase-c agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation:a systematic review and meta-analysis[J].Am J Gastroenterol,2018,113(3):329-338.
[27] NAKAJIMA A,TANIGUCHI S,KUROSU S,et al.Efficacy,long-term safety,and impact on quality of life of elobixibat in more severe constipation:post hoc analyses of two phase 3 trials in Japan[J/OL].Neurogastroenterol Motil,2019,31(5)[2022-12-02].https://doi.org/10.1111/nmo.13571.
[28] HUSSAIN Z H,WHITEHEAD D A,LACY B E.Fecal Impaction[J/OL].Curr Gastroenterol Rep,2014,16(9)[2022-12-02].https://doi.org/10.1007/s11894-014-0404-2.
[29] MORI H,TACK J,SUZUKI H.Magnesium oxide in constipation[J/OL].Nutrients,2021,13(2)[2022-12-02].https://doi.org/10.3390/nu13020421.
[30] RAO S S.Biofeedback therapy for constipation in adults[J].Best Pract Res Clin Gastroenterol,2011,25(1):159-166.
[31] ZHOU S L,ZHANG X L,WANG J H.Comparison of electroacupuncture and medical treatment for functional constipation:a systematic review and meta-analysis[J].Acupunct Med,2017,35(5):324-331.
[32] 于凌. 针灸治疗胸腰椎骨折术后腹胀便秘的临床疗效[J].中外女性健康研究,2018(12):28-29.
[33] BAE S H.Diets for constipation[J].Pediatric Gastroenterol Hepatol Nutr,2014,17(4):203-208.
[34] ROSENBAUM D P,YAN A,JACOBS J W.Pharmacodynamics,safety,and tolerability of the NHE3 inhibitor tenapanor:two trials in healthy volunteers[J].Clin Drug Investig,2018,38(4):341-351.
[35] CAMILLERI M,FORD A C,MAWE G M,et al.Chronic constipation[J/OL].Nat Rev Dis Primers,2017,3(1)[2022-12-02].https://doi.org/10.1038/nrdp.2017.95. |
|
|
|
